MESROOT-800 Mesalamine Delayed Release 800 mg Tablets Division: DIABGLYM Composition Each delayed-release tablet contains: Mesalamine IP — 800 mg Excipients — q.s. Colour: Approved colour used Dosage form: Delayed-release oral tablet Product Description MESROOT-800 contains Mesalamine Delayed Release 800 mg, an advanced anti-inflammatory aminosalicylate formulation designed for the treatment and maintenance of remission in ulcerative colitis and other inflammatory bowel diseases (IBD). The delayed-release formulation ensures targeted drug delivery to the colon, where Mesalamine exerts its local anti-inflammatory action on the intestinal mucosa. Mesalamine is widely prescribed by gastroenterologists for patients with mild to moderate ulcerative colitis, proctosigmoiditis, pancolitis, and long-term maintenance therapy to reduce disease relapse. It helps decrease intestinal inflammation, improve mucosal healing, reduce rectal bleeding and diarrhea, and maintain long-term remission in patients with inflammatory bowel disease. MESROOT-800 is particularly beneficial for patients requiring targeted colonic drug delivery, maintenance of ulcerative colitis remission, long-term mucosal protection, and effective anti-inflammatory therapy with minimal systemic absorption. Technical Knowledge of Mesalamine Delayed Release Mesalamine (5-aminosalicylic acid) acts locally within the intestinal mucosa by inhibiting cyclooxygenase and lipoxygenase pathways, reducing the synthesis of inflammatory prostaglandins and leukotrienes. It also modulates cytokine production, inhibits nuclear factor-kappa B (NF-kB) activation, reduces oxidative stress, and suppresses inflammatory cell migration within the colon. The delayed-release tablet is formulated with pH-dependent coating technology that protects the drug from release in the stomach and proximal small intestine, allowing targeted release in the terminal ileum and colon, where inflammation is most prominent in ulcerative colitis. Mechanism of Action Mesalamine inhibits cyclooxygenase and lipoxygenase pathways, reduces prostaglandin and leukotriene synthesis, suppresses inflammatory cytokines, decreases oxidative stress, promotes mucosal healing, and reduces intestinal inflammation through local colonic action. Key Benefits Targets inflammation directly in the colon Promotes mucosal healing Helps induce and maintain remission in ulcerative colitis Reduces rectal bleeding and diarrhea Provides targeted delayed-release colonic delivery Minimizes systemic drug exposure Supports long-term inflammatory bowel disease management Suitable for long-term therapy under medical supervision Clinical Applications MESROOT-800 is commonly prescribed for mild to moderate ulcerative colitis, extensive ulcerative colitis, pancolitis, proctosigmoiditis, maintenance of ulcerative colitis remission, inflammatory bowel disease, and long-term colonic anti-inflammatory therapy. Facts About Mesalamine Mesalamine is considered first-line therapy for mild to moderate ulcerative colitis and maintenance of remission. Delayed-release formulations are specifically designed to deliver the drug to the colon, improving therapeutic efficacy while minimizing systemic adverse effects. Long-term Mesalamine therapy has demonstrated significant benefits in maintaining remission, promoting mucosal healing, reducing disease relapse, and improving quality of life in patients with ulcerative colitis. Key Facts Delayed-release aminosalicylate therapy Mesalamine 800 mg for targeted colonic anti-inflammatory treatment Promotes mucosal healing and remission maintenance Effective in ulcerative colitis and inflammatory bowel disease Minimizes systemic drug exposure Evidence-based gastroenterology therapy Quality-assured pharmaceutical formulation PCD Pharma Franchise Opportunity MESROOT-800 is an excellent product for PCD Pharma Franchise, Gastroenterology Franchise, and Specialty Pharma Franchise across India. The increasing prevalence of ulcerative colitis, inflammatory bowel disease, gastrointestinal inflammatory disorders, and long-term maintenance therapy creates strong prescription demand and excellent market potential for this formulation. Why Choose MESROOT-800 for PCD Pharma Franchise? High prescription potential Strong gastroenterologist acceptance Attractive monopoly franchise opportunity Competitive pricing Promotional support available Visual aids and specialty marketing inputs Consistent product quality Excellent repeat business potential Third Party Manufacturing Chemsroot Pharmaceutical offers Third Party Manufacturing of Mesalamine Delayed Release 800 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and specialty gastroenterology businesses. Our Third Party Manufacturing Services Include Private label manufacturing Contract manufacturing Custom brand manufacturing Loan license manufacturing DCGI-compliant production GMP-certified manufacturing Batch manufacturing documentation Product registration support Customized packaging and artwork Monopoly franchise packaging Bulk manufacturing capability Manufacturing Features Pharmaceutical-grade raw materials IP/BP/USP quality standards In-process quality control Finished product testing Stability-oriented delayed-release formulation Advanced pH-dependent coating technology Blister and Alu-Alu packaging options MESROOT-800 from DIABGLYM combines targeted colonic anti-inflammatory therapy, mucosal healing support, evidence-based ulcerative colitis management, and high-quality pharmaceutical manufacturing, making it an ideal product for gastroenterologists, physicians, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Mesalamine delayed-release formulation.
Chandigarh
08048035312
+918699304069
Chat with us
Chat with us
